Targets › LAMA3
2 programs from 2 companies in 2 trials: 2 Phase 1; Other.
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.; FUNCTION: Laminin-5 is thought to be involved in (1) cell adhesion via integrin alpha-3/beta-1 in focal adhesion and integrin alpha-6/beta-4 in hemidesmosomes, (2) signal transduction via…. (UniProt, Q16787)
Open in Phaseline: the race on LAMA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fundación DEBRA Chile, Niños Piel de Cristal | ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops) Amniotic fluid secretome containing extracellular matrix proteins (collagen type VII, lami | COL7A1, LAMA3 | Phase 1 | Junctional Epidermolysis Bullosa | – |
| University of Southern California | Gentamicin Bacterial 70S ribosome inhibitor | LAMB3, LAMA3, LAMC2 | Phase 1 | Junctional Epidermolysis Bullosa | – |
Junctional Epidermolysis Bullosa (2)
protein or peptide (1), small molecule (1)
Fundación DEBRA Chile, Niños Piel de Cristal (1) University of Southern California (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.